Alix Ventures
Alix Ventures is a San Francisco-based venture capital firm established in 2019, focused on early-stage life science startups. The firm is dedicated to supporting innovative companies that aim to make significant advancements in human health through the integration of technology and biology. Alix Ventures emphasizes the importance of partnering with passionate and experienced founders who possess unique insights to tackle pressing challenges in the life sciences sector. The team comprises seasoned entrepreneurs with backgrounds in venture capital and extensive experience in raising capital, scaling operations, and navigating regulatory complexities. Additionally, the firm has assembled a scientific and medical advisory board of accomplished PhD founders to enhance technical and clinical diligence. Alix Ventures prioritizes the success of its portfolio companies by offering a comprehensive platform of resources, including support for customer introductions, fundraising, and team building, while leveraging a robust network of industry executives from top pharmaceutical companies and health systems.
15 past transactions
Galatea Bio
Venture Round in 2025
Galatea Bio is a biotechnology company based in the United States, founded by Carlos Bustamante, Nicholas Katsanis, and Alexander Ioannidis. The company focuses on improving diagnostic testing and accelerating drug discovery specifically for diverse and underserved populations that have historically been underrepresented in genetics research. Galatea Bio operates a biobank that serves as a biosample and bioinformatics platform, utilizing advanced algorithms and innovative analyses to facilitate genomic discoveries. Through its world-class clinical network, the company aims to identify patients at risk for severe multi-inflammatory syndromes or infections, ultimately working to develop new tests, treatments, and cures that enhance healthcare outcomes for all.
Elegen
Series B in 2024
Elegen is a biotechnology company founded in 2017 and led by Dr. Matthew Hill, specializing in the development of microfluidic technology. The company focuses on creating innovative DNA synthesizers that enhance the engineering of entire genomes. By leveraging its advanced technology, Elegen aims to accelerate biomedical advancements and facilitate DNA sequence testing within the healthcare industry. Through its commitment to disrupting synthetic biology, Elegen is positioned to play a pivotal role in the future of genetic research and applications.
Zafrens
Series A in 2023
Zafrens is a drug discovery company founded in 2021 and headquartered in San Diego, California. It focuses on developing life sciences products that facilitate the detailed characterization of diverse cell populations. The company's innovative platform provides a resolution approach to studying interactions between cells and drugs, as well as between different cell types, by directly mapping the molecular states of individual cells. Zafrens leverages large volumes of curated experimental data to train artificial intelligence models for drug discovery, enhancing its capabilities in T cell immunotherapies and ribonucleic acid regulation. By integrating insights from biology, chemistry, and engineering, Zafrens aims to advance the medical industry with its proprietary data and experimental techniques.
Chemify
Series A in 2023
Chemify specializes in developing a chemical digitization platform designed to facilitate drug and materials discovery as well as chemical synthesis. The company's innovative approach involves using automated synthetic hardware combined with digital XDL code to convert code into molecules on demand. This system is modular, universal, scalable, and teachable, making it highly versatile for various applications in chemical and material research. Chemify's software includes a unique chemical programming language and natural language recognition capabilities that translate synthetic procedures efficiently. Additionally, the platform features a comprehensive ontology that provides detailed insights into reaction conditions and flags potential issues, offering scientists real-time telemetry of reactions.
Xilis
Series A in 2022
Xilis, Inc. is a biotechnology company founded in 2019 and based in Chapel Hill, North Carolina. The company specializes in developing next-generation organoid technologies aimed at guiding precision therapy for cancer patients and enhancing drug discovery processes. Its flagship platform, XilisµO, facilitates rapid diagnostics, personalized drug screening, and the creation of scalable patient-derived models, which support high-throughput drug discovery. By enabling both physicians and pharmaceutical companies to conduct tailored drug screenings, Xilis aims to lower costs and improve treatment outcomes for cancer patients.
Zafrens
Seed Round in 2021
Zafrens is a drug discovery company founded in 2021 and headquartered in San Diego, California. It focuses on developing life sciences products that facilitate the detailed characterization of diverse cell populations. The company's innovative platform provides a resolution approach to studying interactions between cells and drugs, as well as between different cell types, by directly mapping the molecular states of individual cells. Zafrens leverages large volumes of curated experimental data to train artificial intelligence models for drug discovery, enhancing its capabilities in T cell immunotherapies and ribonucleic acid regulation. By integrating insights from biology, chemistry, and engineering, Zafrens aims to advance the medical industry with its proprietary data and experimental techniques.
Pair Team
Seed Round in 2021
Pair Team is dedicated to enhancing primary care infrastructure for vulnerable communities, focusing on Medicaid and Medicare patients. As the first tech-enabled care team, they support safety-net primary care systems by acting as an extension of clinical staff, delivering personalized and high-touch care experiences. Their approach addresses various barriers to healthcare access, including transportation issues, housing and food insecurity, and limitations in mobile phone access. To facilitate effective care delivery, Pair Team is developing a unique platform that ensures adherence to clinical best practices, integrates services with community-based organizations, and automates administrative tasks, allowing clinicians to concentrate more on patient interaction. The company employs a diverse team of professionals, including community health workers, registered nurses, and behavioral health clinicians, to provide comprehensive support tailored to the needs of low-income individuals, thereby promoting a holistic and patient-centered care model.
Elegen
Series A in 2021
Elegen is a biotechnology company founded in 2017 and led by Dr. Matthew Hill, specializing in the development of microfluidic technology. The company focuses on creating innovative DNA synthesizers that enhance the engineering of entire genomes. By leveraging its advanced technology, Elegen aims to accelerate biomedical advancements and facilitate DNA sequence testing within the healthcare industry. Through its commitment to disrupting synthetic biology, Elegen is positioned to play a pivotal role in the future of genetic research and applications.
Zafrens
Pre Seed Round in 2021
Zafrens is a drug discovery company founded in 2021 and headquartered in San Diego, California. It focuses on developing life sciences products that facilitate the detailed characterization of diverse cell populations. The company's innovative platform provides a resolution approach to studying interactions between cells and drugs, as well as between different cell types, by directly mapping the molecular states of individual cells. Zafrens leverages large volumes of curated experimental data to train artificial intelligence models for drug discovery, enhancing its capabilities in T cell immunotherapies and ribonucleic acid regulation. By integrating insights from biology, chemistry, and engineering, Zafrens aims to advance the medical industry with its proprietary data and experimental techniques.
Teiko.bio
Venture Round in 2021
Teiko.bio is an immune profiling company founded in 2020 and based in Salt Lake City, Utah. The company has developed a platform that identifies immune features linked to patient response, assesses the abundance and activation scores of various immune cell types, and suggests rational targets for combination therapies. By enabling clinicians to make informed treatment decisions, Teiko.bio aims to enhance patient outcomes and facilitate new discoveries in therapeutic pathways.
Xilis
Series A in 2021
Xilis, Inc. is a biotechnology company founded in 2019 and based in Chapel Hill, North Carolina. The company specializes in developing next-generation organoid technologies aimed at guiding precision therapy for cancer patients and enhancing drug discovery processes. Its flagship platform, XilisµO, facilitates rapid diagnostics, personalized drug screening, and the creation of scalable patient-derived models, which support high-throughput drug discovery. By enabling both physicians and pharmaceutical companies to conduct tailored drug screenings, Xilis aims to lower costs and improve treatment outcomes for cancer patients.
Elegen
Seed Round in 2020
Elegen is a biotechnology company founded in 2017 and led by Dr. Matthew Hill, specializing in the development of microfluidic technology. The company focuses on creating innovative DNA synthesizers that enhance the engineering of entire genomes. By leveraging its advanced technology, Elegen aims to accelerate biomedical advancements and facilitate DNA sequence testing within the healthcare industry. Through its commitment to disrupting synthetic biology, Elegen is positioned to play a pivotal role in the future of genetic research and applications.
Xilis
Seed Round in 2020
Xilis, Inc. is a biotechnology company founded in 2019 and based in Chapel Hill, North Carolina. The company specializes in developing next-generation organoid technologies aimed at guiding precision therapy for cancer patients and enhancing drug discovery processes. Its flagship platform, XilisµO, facilitates rapid diagnostics, personalized drug screening, and the creation of scalable patient-derived models, which support high-throughput drug discovery. By enabling both physicians and pharmaceutical companies to conduct tailored drug screenings, Xilis aims to lower costs and improve treatment outcomes for cancer patients.
Circularis Biotechnologies
Seed Round in 2020
Circularis Biotechnologies, Inc. is a biotechnology company founded in 2014 and headquartered in Oakland, California. The company specializes in developing innovative methods to regulate gene expression, which enhances the production yields of biotherapeutics. Circularis offers a range of products, including RACRE Variant Libraries, hCMV Variant Library, Protein expression with CMV promoters, and T7 Variant Library. In addition, it provides various services such as RACRE Enhancement, RACRE Discovery, RACRE Technology Access Program, and Ribozyme Analysis of Cis-Regulatory Elements. Through its advanced technologies and services, Circularis aims to improve the efficiency and effectiveness of biotherapeutic production.
Pair Team
Seed Round in 2019
Pair Team is dedicated to enhancing primary care infrastructure for vulnerable communities, focusing on Medicaid and Medicare patients. As the first tech-enabled care team, they support safety-net primary care systems by acting as an extension of clinical staff, delivering personalized and high-touch care experiences. Their approach addresses various barriers to healthcare access, including transportation issues, housing and food insecurity, and limitations in mobile phone access. To facilitate effective care delivery, Pair Team is developing a unique platform that ensures adherence to clinical best practices, integrates services with community-based organizations, and automates administrative tasks, allowing clinicians to concentrate more on patient interaction. The company employs a diverse team of professionals, including community health workers, registered nurses, and behavioral health clinicians, to provide comprehensive support tailored to the needs of low-income individuals, thereby promoting a holistic and patient-centered care model.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.